LEGN Stock Analysis: Legend Biotech | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 3.790m USD | 12M Return: -43.6% | US52490G1022 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 45.2M
Qual. Beats: 1
Rev. Trend: 98.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 6.4 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Legend Biotech Corporation (LEGN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications, operating primarily in the United States, China, and Europe. Headquartered in Somerset, New Jersey, and founded in 2014, the company focuses on advancing chimeric antigen receptor (CAR-T) therapies and related cell-based treatments.
Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), is a BCMA-directed CAR-T therapy for multiple myeloma (MM), developed and commercialized in partnership with Janssen Biotech under a collaboration and license agreement. The CAR-T class represents a personalized form of cell therapy in which a patients own T-cells are genetically engineered to target cancer, and Legends partnership with Janssen positions it within a competitive MM CAR-T landscape that also includes Bristol-Myers Squibbs ide-cel (Abecma).
Beyond cilta-cel, Legend maintains a broad pipeline of earlier-stage autologous CAR-T candidates targeting cancers such as acute lymphoblastic leukemia, gastric, esophageal, pancreatic, colorectal, and lung cancers. The company is also developing allogeneic gamma delta CAR-T and CAR-NK therapies aimed at BCMA for MM, currently in investigator-initiated Phase 1 trials in China. Additionally, Legend holds a license agreement with Novartis Pharma AG to develop CAR-T therapies targeting delta-like ligand protein 3 (DLL3), an antigen associated with small cell lung cancer.
- Carvykti sales surge on expanding multiple myeloma market share
- Competition from Bristol Myers Abecma pressures market position
- Manufacturing scale-up drives Carvykti supply and revenue growth
| Net Income: -215k TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.19 > 0.02 and ΔFCF/TA -8.07 > 1.0 |
| NWC/Revenue: 62.95% < 20% (prev 88.94%; Δ -25.99% < -1%) |
| CFO/TA -0.15 > 3% & CFO -247.8m > Net Income -215k |
| Net Debt (-561.8m) to EBITDA (99.5m): -5.64 < 3 |
| Current Ratio: 3.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (193.8m) vs 12m ago 4.96% < -2% |
| Gross Margin: 56.98% > 18% (prev 60.55%; Δ -3.57% > 0.5%) |
| Asset Turnover: 80.04% > 50% (prev 53.06%; Δ 26.98% > 0%) |
| Interest Coverage Ratio: 3.27 > 6 (EBIT TTM 49.3m / Interest Expense TTM 15.1m) |
| A: 0.51 (Total Current Assets 1.14b - Total Current Liabilities 289.6m) / Total Assets 1.68b |
| B: -1.15 (Retained Earnings -1.93b / Total Assets 1.68b) |
| C: 0.03 (EBIT TTM 49.3m / Avg Total Assets 1.70b) |
| D: 3.11 (Book Value of Equity 1.27b / Total Liabilities 408.7m) |
| Altman-Z'' = 3.06 = A |
| DSRI: 0.72 (Receivables 218.9m/202.6m, Revenue 1.36b/909.0m) |
| GMI: 1.06 (GM 60.55% / 56.98%) |
| AQI: 0.46 (AQ_t 0.06 / AQ_t-1 0.13) |
| SGI: 1.49 (Revenue 1.36b / 909.0m) |
| TATA: 0.15 (NI -215k - CFO -247.8m) / TA 1.68b) |
| Beneish M = -3.15 (Cap -4..+1) = AA |
As of November 14, 2026, the stock is trading at USD 17.50 with a total of 3,028,917 shares traded. Over the past week, the price has changed by -25.21%, over one month by -2.13%, over three months by -13.67% and over the past year by -43.57%.
Current recommended Stop Loss: 15.70 (which is 10.3% or 1.2 ATR below the current price).
Legend Biotech has received a consensus analysts rating of 3.85. Therefore, it is recommended to buy LEGN.
- StrongBuy: 3
- Buy: 5
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 42.7 | 143.9% |
P/E Forward = 24.0385
P/S = 2.79
P/B = 3.1106
Revenue TTM = 1.36b USD
EBIT TTM = 49.3m USD
EBITDA TTM = 99.5m USD
Long Term Debt = 111.5m USD (estimated: total debt 167.4m - short term 55.9m)
Short Term Debt = 55.9m USD (from shortTermDebt, last quarter)
Debt = 290.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 123.3m
Net Debt = -561.8m USD (calculated: Debt 290.7m - CCE 852.5m)
Enterprise Value = 3.23b USD (3.79b + Debt 290.7m - CCE 852.5m)
Interest Coverage Ratio = 3.27 (Ebit TTM 49.3m / Interest Expense TTM 15.1m)
EV/FCF = -10.06x (Enterprise Value 3.23b / FCF TTM -320.9m)
FCF Yield = -9.94% (FCF TTM -320.9m / Enterprise Value 3.23b)
FCF Margin = -23.62% (FCF TTM -320.9m / Revenue TTM 1.36b)
Net Margin = -0.02% (Net Income TTM -215k / Revenue TTM 1.36b)
Gross Margin = 56.98% ((Revenue TTM 1.36b - Cost of Revenue TTM 584.4m) / Revenue TTM)
Gross Margin QoQ = 58.94% (prev 64.54%)
Tobins Q-Ratio = 1.92 (Enterprise Value 3.23b / Total Assets 1.68b)
Interest Expense / Debt = 5.19% (Interest Expense 15.1m / Debt 290.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 38.9m (EBIT 49.3m * (1 - 21.00%))
Current Ratio = 3.95 (Total Current Assets 1.14b / Total Current Liabilities 289.6m)
Debt / Equity = 0.23 (Debt 290.7m / totalStockholderEquity, last quarter 1.27b)
Debt / EBITDA = -5.64 (Net Debt -561.8m / EBITDA 99.5m)
Debt / FCF = 1.75 (negative FCF - burning cash) (Net Debt -561.8m / FCF TTM -320.9m)
Total Stockholder Equity = 1.12b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.01% (Net Income -215k / Total Assets 1.68b)
RoE = -0.02% (Net Income TTM -215k / Total Stockholder Equity 1.12b)
RoCE = 4.01% (EBIT 49.3m / Capital Employed (Equity 1.12b + L.T.Debt 111.5m))
RoIC = 2.82% (NOPAT 38.9m / Invested Capital 1.38b)
WACC = 9.36% (E(3.79b)/V(4.08b) * Re(9.76%) + D(290.7m)/V(4.08b) * Rd(5.19%) * (1-Tc(0.21)))
Discount Rate = 9.76% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 81.43 | Cagr: 2.68%
[DCF] Fair Price = unknown (Cash Flow -320.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.99 | # QB: 1
Revenue Correlation: 98.75 | Revenue CAGR: 74.94% | SUE: -0.02 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.13 | Chg30d=+0.00% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.01 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+99.4% | GrowthRev=+38.7%
EPS next Year (2027-12-31): EPS=0.70 | Chg30d=+1.77% | Revisions=+0% | GrowthEPS=+6621.9% | GrowthRev=+18.8%
[Analyst] Revisions Ratio: +0% (up=0, down=0)